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SMaRT Technology Enables Gene 
Expression Repair in Skin Gene 
Therapy
Ulrich R. Hengge1
In this issue, Wally et al. (2008) report successful gene expression repair by 
spliceosome-mediated RNA trans-splicing (SMaRT), a novel achievement in 
molecular medicine. In their model, SMaRT was able to replace a mutation 
of the plectin gene in epidermolysis bullosa simplex with muscular dystrophy. 
This approach is particularly attractive for skin gene therapy of dominant-neg-
ative mutations present in a number of blistering genodermatoses.
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Wally et al. (this issue, 2008) describe 
successful execution of gene expres-
sion repair, a novel achievement in 
molecular medicine. The authors have 
used spliceosome-mediated RNA 
trans-splicing (SMaRT), which is able 
to replace certain mRNA exonic seg-
ments of defective genes. This approach 
is particularly attractive for the correc-
tion of dominant-negative mutations 
present in a number of blistering geno-
dermatoses (Uitto and Richard, 2004). 
This technology will restore not only 
the expression of the corrected mRNA 
from the dominant-negative gene but 
also the production of the correspond-
ing protein. Although trans-splicing 
has been successfully used for the cor-
rection of the cystic fibrosis transmem-
brane receptor and the β-globin gene 
(Liu et al., 2002; Chao et al., 2003), it 
has not been pioneered for correcting 
dominant-negative mutations of geno-
dermatoses such as the plectin gene 
in epidermolysis bullosa simplex with 
muscular dystrophy.
Advantages of this technology 
include the possibility of utilizing small 
corrective RNA sequences that target 
exonic sequences within the mutated 
gene with high specificity as well as the 
natural regulation of gene expression. 
Consequently, these small corrective 
RNA sequences may be efficiently 
packaged in retroviral or lentiviral vec-
tors that have a limited capacity to carry 
large genes, such as the plectin gene 
that codes for a 14.2-kDa RNA. In this 
study, retroviral gene transfer has yield-
ed increasing amounts of correct plectin 
protein. Several private mutations con-
tained in hot-spot areas can be targeted 
with a few pre trans-splicing RNAs, thus 
making SMaRT technology applicable 
to a larger number of patients.
Limitations of the SMaRT techno-
logy are its relatively low efficiency 
and the optimal design of the pre 
trans-splicing molecules that must 
specifically recombine with target 
intronic pre RNA, e.g., using function-
al splice sites (Mansfield et al., 2003).
Short interfering RNA has previously 
been used to knock out the mutated 
gene/gene product that exhibited off-
target effects and was found to silence 
expression from the normal allele, which 
counteracts normal protein expression 
in dominant-negative diseases.
The new technology must compete 
with other molecular therapies such 
as gene replacement or supplemen-
tation therapy in which, for example, 
Sleeping Beauty transposons or ΦC31 
bacterial phage integrases were used 
to integrate wild-type gene copies 
into the genome (Ortiz-Urda et al., 
2003a,b). Alternatively, zinc finger 
proteins have recently been used for 
true gene correction and were found 
to restore normal gene expression 
(Urnov et al., 2005).
Last, although the achieved prog-
ress is greatly appreciated—and 
necessary if skin gene therapy is 
to be kept alive—some obstacles 
to successful gene therapy remain 
unresolved. The first is the random 
insertion of retroviral vectors that has 
corrected the life-threatening severe 
combined immune deficiency syn-
drome (“bubble babies”) in more than 
70% of treated individuals through-
out the world (Hacein-Bey-Abina et 
al., 2003) but has also caused sev-
eral cases of leukemia when vectors 
inserted into cellular oncogenes (e.g., 
LMO2 or evi-1). Second, the inactiva-
tion of gene expression following ret-
roviral or lentiviral gene transfer limits 
the longevity of the desired effects to 
several months. Ultimately, the use 
of suitable animal models will reveal 
the full benefit of this new technology 
(Arin and Roop, 2004).
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